OTCMKTS:VACBF Nykode Therapeutics AS (VACBF) Stock Price, News & Analysis $0.52 -0.01 (-1.26%) (As of 09/13/2024) Add Compare Share Share Stock Analysis Stock AnalysisChartShort Interest About Nykode Therapeutics AS Stock (OTCMKTS:VACBF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nykode Therapeutics AS alerts:Sign Up Key Stats Today's Range$0.52▼$0.5250-Day Range$0.52▼$1.5052-Week Range$0.52▼$0.95Volume500 shsAverage Volume500 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.Read More… Notice: Major payout due November 19th - are you on the list? (Ad)On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...Click here for the ticker >>> Receive VACBF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nykode Therapeutics AS and its competitors with MarketBeat's FREE daily newsletter. Email Address VACBF Stock News HeadlinesNykode Therapeutics AS (5VB.DU)September 17, 2024 | finance.yahoo.comNykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based VaccinesAugust 14, 2024 | globenewswire.com25-Yr Wall St Legend: Get Out of Cash before Nov 6Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.October 7, 2024 | Stansberry Research (Ad)Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 MeetingJune 20, 2024 | globenewswire.comNykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior EfficacyJune 11, 2024 | globenewswire.comNykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical CancerMay 14, 2024 | globenewswire.comNykode Therapeutics - Quarterly report Q1 2024May 14, 2024 | globenewswire.comNykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical CancerApril 19, 2024 | globenewswire.comSee More Headlines VACBF Stock Analysis - Frequently Asked Questions How have VACBF shares performed this year? Nykode Therapeutics AS's stock was trading at $1.58 at the beginning of 2024. Since then, VACBF shares have decreased by 67.1% and is now trading at $0.5191. View the best growth stocks for 2024 here. How do I buy shares of Nykode Therapeutics AS? Shares of VACBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:VACBF CUSIPN/A CIKN/A Webnykode.com Phone47-22-95-81-93FaxN/AEmployees171Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (OTCMKTS:VACBF) was last updated on 10/7/2024 by MarketBeat.com Staff From Our PartnersBiden Deploys Phase 1 Fednow Digital CurrencyIf Kamala can steal the election…She'll steal your financial freedom next.American Alternative | SponsoredStrikes and Economic Unrest: Are You Prepared for What’s Coming?The rapid advancement of artificial intelligence and automation is reshaping industries and posing threats to ...InvestorPlace | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNew President Kamala warningFinancial nightmare coming after election In 2018, one independent research predicted Kamala Harris was on ...Stansberry Research | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | Sponsored10X More Profitable Than Physical Gold?The smart money is piling into gold and gold stocks. There's a backdoor gold play that could deliver 10 TIM...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nykode Therapeutics AS Please log in to your account or sign up in order to add this asset to your watchlist. Share Nykode Therapeutics AS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.